KALV News and Press, KalVista Pharmaceuticals Inc. From 02/16/24

2024-02-16 16:31:07 ET More on KalVista Pharmaceticals KalVista Is Still Cheap After Phase 3 Hereditary Angioedema Data KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade) KalVista Pharmaceuticals up 16%, prices $160M offering...

– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibito...

2024-02-15 12:18:48 ET Summary KalVista Pharmaceutical announces positive phase 3 data for its oral therapy, sebetralstat, for hereditary angioedema. Sebetralstat's rapid onset of symptom relief, oral administration, and favorable safety profile give it a competitive edge in the o...

2024-02-15 06:43:24 ET More on KalVista Pharmaceticals KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade) KalVista: On Demand Oral Treatment For HAE Signifies Differentiated Advancement Two biotech/pharma stocks to watch - ST...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of its underwritten public offering of (i) 7,016,312 shares of its common stock at a price to the public of $15.25 per share and (ii) pre-funded warrants to purchase 3,483,688 shares of common sto...

2024-02-14 16:29:45 ET KalVista Pharmaceuticals ( NASDAQ: KALV ) intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of common stock in lieu of KalVista common stock to certain investors in an underwritten public offering. In additio...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) announced today that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of common stock in lieu of KalVista common stock to certain investors in an underwritten public offering...

2024-02-14 14:31:52 ET Summary Sebetralstat has a compelling drug profile for the on-demand treatment of HAE attacks and could become the new standard of care in a billion-dollar market opportunity. KalVista is transitioning to a commercial company following positive Phase 3 data ...

2024-02-14 00:18:03 ET Read the full article on Seeking Alpha For further details see: Two Biotech/pharma stocks to watch - STTK, KALV

2024-02-13 08:18:56 ET DENVER, Colo., Feb. 13, 2024 ( www.247marketnews.com )- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) reported, this morning, positive results from the phase 3 KONFIDENT clinical trial demonstrating statistically and clinically significant efficacy of sebetralstat ...